Analysts expect Acadia Healthcare Company Inc (NASDAQ:ACHC) to report $784.15 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Acadia Healthcare’s earnings, with the lowest sales estimate coming in at $773.20 million and the highest estimate coming in at $827.90 million. Acadia Healthcare reported sales of $743.55 million during the same quarter last year, which indicates a positive year over year growth rate of 5.5%. The firm is expected to issue its next earnings results on Thursday, February 27th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Acadia Healthcare will report full year sales of $3.10 billion for the current fiscal year, with estimates ranging from $3.10 billion to $3.11 billion. For the next fiscal year, analysts forecast that the company will post sales of $3.27 billion, with estimates ranging from $3.21 billion to $3.39 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Acadia Healthcare.
Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.03). Acadia Healthcare had a negative net margin of 6.88% and a positive return on equity of 7.31%. The business had revenue of $777.25 million during the quarter, compared to analyst estimates of $790.39 million. During the same period in the previous year, the firm posted $0.55 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis.
ACHC has been the subject of a number of research analyst reports. UBS Group boosted their target price on shares of Acadia Healthcare from $29.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Raymond James lowered shares of Acadia Healthcare from a “strong-buy” rating to an “outperform” rating and set a $45.00 target price for the company. in a research report on Wednesday, July 31st. Zacks Investment Research lowered shares of Acadia Healthcare from a “hold” rating to a “sell” rating and set a $31.00 target price for the company. in a research report on Wednesday, August 7th. Jefferies Financial Group set a $40.00 target price on shares of Acadia Healthcare and gave the stock a “buy” rating in a research report on Thursday, October 10th. Finally, ValuEngine raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $36.00.
Acadia Healthcare stock opened at $31.50 on Monday. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of 14.06, a P/E/G ratio of 1.46 and a beta of 0.66. The company has a debt-to-equity ratio of 1.49, a current ratio of 1.17 and a quick ratio of 1.17. Acadia Healthcare has a fifty-two week low of $24.27 and a fifty-two week high of $39.31. The firm has a fifty day moving average price of $30.39 and a two-hundred day moving average price of $31.30.
In other Acadia Healthcare news, CEO Debra K. Osteen acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were acquired at an average cost of $26.53 per share, for a total transaction of $530,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 117,178 shares of the company’s stock, valued at approximately $3,108,732.34. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Abrams Bison Investments LLC acquired a new stake in Acadia Healthcare in the second quarter worth $83,531,000. Nuveen Asset Management LLC acquired a new stake in Acadia Healthcare in the second quarter worth $8,508,000. Stephens Investment Management Group LLC raised its holdings in Acadia Healthcare by 13.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,300,936 shares of the company’s stock worth $40,433,000 after purchasing an additional 158,081 shares during the period. GW&K Investment Management LLC raised its holdings in Acadia Healthcare by 31.6% in the second quarter. GW&K Investment Management LLC now owns 632,216 shares of the company’s stock worth $22,096,000 after purchasing an additional 151,737 shares during the period. Finally, Rock Springs Capital Management LP raised its holdings in Acadia Healthcare by 14.1% in the second quarter. Rock Springs Capital Management LP now owns 1,055,000 shares of the company’s stock worth $36,872,000 after purchasing an additional 130,000 shares during the period.
About Acadia Healthcare
Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico.
Recommended Story: What causes a stock to be most active?
For more information about research offerings from Zacks Investment Research, visit Zacks.com